Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

William Blair has initiated coverage on Denali Therapeutics Inc DNLI, a company focused on developing drugs for neurodegenerative diseases.The analyst highlights that Denali is developing a specialized transport vehicle (TV) platform to enhance the delivery of treatments across the blood-brain barrier.It stands out from competitors with its promising potential for top-tier performance and scalability across different therapies and conditions.The company’s lead program Tividenofusp alfa, an enzyme-replacemen ...